Interlaced: Our Purpose Woven into Art

Interlaced: Our Purpose Woven into Art

Several yellow shoelaces interlaced together with writing

What might look like an ordinary wreath displayed at our U.S. headquarters is a powerful symbol of our collective hope and united purpose—to serve patients with compassion.

The focal point of “Interlaced” is a bow created from yellow and white shoelaces, dedicated by Daiichi Sankyo employees from the United States, Europe and Japan to people in their lives who have been touched by cancer. They include tributes to loved ones as well as messages of support to family members, friends and all patients living with the disease.

The shoelace dedication, woven into an artistic reminder of our collective compassion for patients, is the cornerstone of our In Their Shoes initiative, a series of opportunities to learn, grow and strengthen our patient mindset. The handwoven wreaths were inspired by traditional Shimenawa in honor of Daiichi Sankyo’s Japanese heritage. Shimenawa are lengths of straw or hemp rope used to demark sacred spaces and ward off disease in the Shinto religion. Shimenawa are traditionally displayed at the entrances of homes in Japan at the start of a new year.

Inspired by the courageous patients and fearless advocates who selflessly share their experiences with us, “Interlaced” is a daily reminder of their stories, our proud heritage and the compassion of our employees woven together.



A Career in Medicine Sparked by a Single Moment NEW

A career of building hope for people with cancer began with a single childhood moment for our Vice President, Global Team Leader, Oncology Research & Development, Dalila Sellami, MD.

View more
Turning Fellowship Into A Fulfilling Healthcare Career

In partnership with the Ernest Mario School of Pharmacy at Rutgers University, Daiichi Sankyo's PharmD fellowship program provides hands-on experience and exposure to the pharmaceutical industry

View more
Looking Towards the Future of Oncology Treatment

At Daiichi Sankyo, Inc., we aim to create essential medicine for longer, better lives. The core and catalyst behind our oncology development plan is our DXd ADC Technology. ADCs, or antibody drug conjugates, are therapies that combine 3 components—an antibody connected to a payload via a linker.

View more